ScholarIQanswers from OpenAlex & ORCID
Judith Raimbourg
ResearcherPublications, citations & collaboration network
Judith Raimbourg is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Judith Raimbourg have?
ScholarIQindexed works
Judith Raimbourg has 189 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Judith Raimbourg have?
ScholarIQcitation count
Judith Raimbourg has 2,757 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Judith Raimbourg?
ScholarIQh-index
Judith Raimbourg has an h-index of 20 in OpenAlex.
What is the i10-index of Judith Raimbourg?
ScholarIQi10-index
Judith Raimbourg has an i10-index of 32 in OpenAlex.
What is the ORCID of Judith Raimbourg?
ScholarIQorcid
The ORCID for Judith Raimbourg is on the source record.
What is the OpenAlex record for Judith Raimbourg?
ScholarIQopenalex
The OpenAlex for Judith Raimbourg is on the source record.
What are the most-cited papers on Judith Raimbourg?
ScholarIQmost cited works
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
Manish A. Shah, Takashi Kojima, Daniel Hochhauser, Peter C. Enzinger, Judith Raimbourg, Antoine Hollebecque, Florian Lordick, Sung‐Bae Kim, Masahiro Tajika, Heung Tae Kim, A. Craig Lockhart, Hendrik-Tobias Arkenau, Farid El-Hajbi, Mukul Gupta, Per Pfeiffer, Qi Liu, Jared Lunceford, Soonmo Peter Kang, Pooja Bhagia, Ken Kato
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Myriam Delaunay, J. Cadranel, Amélie Lusque, Nicolás Meyer, V. Gounant, Denis Moro‐Sibilot, Jean‐Marie Michot, Judith Raimbourg, Nicolas Girard, Florian Guisier, David Planchard, Anne-Cécile Métivier, Pascale Tomasini, Éric Dansin, M. Pérol, M. Campana, Oliver Gautschi, Martin Früh, Jean-David Fumet, Clarisse Audigier-Valette, S. Couraud, Stéphane Dalle, M.‐T. Leccia, M. Jaffro, S. Collot, Grégoire Prévôt, Julie Milia, Julien Mazières
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Clarisse Audigier-Valette, Jacobus A. Burgers, Adam Płużański, Randeep Sangha, Carlos Gallardo, Masayuki Takeda, Helena Linardou, Lorena Lupinacci, Ki Hyeong Lee, Claudia Caserta, Mariano Provencio, Enric Carcereny, Gregory A. Otterson, Michael Schenker, Bogdan Żurawski, Aurelia Alexandru, A. Vergnenègre, Judith Raimbourg, Kynan Feeney, Sang‐We Kim, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O’Neil, John M. Wallmark, David Lorente, Elena Élez, Judith Raimbourg, Carlos Gomez‐Roca, Samuel Ejadi, Sarina A. Piha‐Paul, Mark N. Stein, Albiruni R. Abdul Razak, Katia Dotti, Armando Santoro, Roger B. Cohen, M. Gould, Sanatan Saraf, Karen Stein, Sae‐Won Han
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Martin Reck, Michael Schenker, Ki Hyeong Lee, Mariano Provencio, Makoto Nishio, Krzysztof Leśniewski-Kmak, Randeep Sangha, Samreen Ahmed, Judith Raimbourg, Kynan Feeney, R. Corre, Fábio Franke, Eduardo Richardet, John R. Penrod, Yong Yuan, Faith E. Nathan, Prabhu Bhagavatheeswaran, Michael DeRosa, Fiona Taylor, Rachael Lawrance, Julie R. Brahmer